Exhibit 107
Calculation of Filing Fee Tables
Form F-1
(Form Type)
TC Biopharm (Holdings) PLC
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities
Security Type | Security Class Title | Fee Calculation or Carry Forward Rule | Maximum Aggregate Offering Price | Fee Rate | Amount of Registration Fee | |||||||||||||||
| Fees to be paid | Equity | Ordinary Shares, par value £0.0001 per share (1)(2)(3) | 457 | (o) | $ | 5,000,000.00 | $ | .00014760 | $ | 738.00 | ||||||||||
| Other | Series G Warrants to purchase American Depositary Shares (4) | 457 | (g) | — | — | $ | 0.00 | |||||||||||||
| Equity | Ordinary Shares issuable upon exercise of Series G Warrants (1)(2) | 457 | (o) | $ | 5,000,000.00 | $ | .00014760 | $ | 738.00 | |||||||||||
| Other | Pre-Funded Warrants to purchase American Depositary Shares (4) | 457 | (g) | — | — | $ | 0.00 | |||||||||||||
| Equity | Ordinary Shares issuable upon exercise of Pre-Funded Warrants (1)(2)(3) | 457 | (o) | — | — | $ | 0.00 | |||||||||||||
| Other | Placement Agent Warrants to purchase American Depositary Shares (4) | 457 | (g) | — | — | $ | 0.00 | |||||||||||||
| Equity | Ordinary Shares issuable upon exercise of Placement Agent Warrants (2)(5) | 457 | (o) | $ | 468,750.00 | $ | .00014760 | $ | 69.19 | |||||||||||
| Total Offering Amounts | $ | 10,468,750.00 | ||||||||||||||||||
| Total Fees Previously Paid | $ | 0 | ||||||||||||||||||
| Total Fee Offsets | $ | 0 | ||||||||||||||||||
| Net Fee Due | $ | 1,545.19 | ||||||||||||||||||
| (1) | Represents the maximum number of ordinary shares, represented by American Depositary Shares (“ADSs”), each representing twenty (20) ordinary shares, offered in this Registration Statement. |
| (2) | This Registration Statement includes an indeterminate number of additional ordinary shares issuable for no additional consideration pursuant to any stock dividend, stock split, recapitalization or other similar transaction effected without the receipt of consideration, which results in an increase in the number of outstanding ordinary shares. In the event of a stock split, stock dividend or similar transaction involving our common stock, in order to prevent dilution, the number of shares registered shall be automatically increased to cover the additional shares in accordance with Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”). |
| (3) | The proposed maximum aggregate offering price of the ADSs will be reduced on a dollar-for-dollar basis based on the offering price of any pre-funded warrants issued in the offering, and the proposed maximum aggregate offering price of the pre-funded warrants to be issued in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any ADS issued in the offering. Accordingly, the proposed maximum aggregate offering price of the ADSs and pre-funded warrants (including the ordinary shares issuable upon exercise of the pre-funded warrants), if any, is $5,000,000.00. |
| (4) | No separate registration fee required pursuant to Rule 457(g) under the Securities Act |
| (5) | Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(g) under the Securities Act. The placement agent warrants are exercisable for up to the number of ADSs or pre-funded warrants equal to 7.5% of the aggregate number of securities sold in this offering at a per ADS exercise price equal to 125% of the public offering price of the ADSs. As estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(g) under the Securities Act, the proposed maximum aggregate offering price of the representative’s warrants is $468,750, which is equal to 125% of $375,000 (7.5% of the proposed maximum aggregate offering price of $5,000,000). |